BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 32492765)

  • 1. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Son WJ; Roh YH; Chung YE; Choi JY; Park MS
    Gut Liver; 2023 May; 17(3):466-474. PubMed ID: 36317516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria.
    Yoon JK; Lee S; Hwang JA; Lee JE; Kim SS; Kim MJ
    J Liver Cancer; 2023 Mar; 23(1):157-165. PubMed ID: 37384026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria.
    Yoon JK; Han DH; Lee S; Choi JY; Choi GH; Kim DY; Kim MJ
    Cancer Res Treat; 2023 Jul; 55(3):939-947. PubMed ID: 36791769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
    Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates.
    Jeon SK; Lee JM; Joo I; Yoo J; Park JY
    Eur Radiol; 2020 Sep; 30(9):4762-4771. PubMed ID: 32333148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
    Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
    Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
    Byun J; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Hepatol Int; 2020 Jul; 14(4):534-543. PubMed ID: 32314171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients.
    Park SH; Shim YS; Kim B; Kim SY; Kim YS; Huh J; Park JH; Kim KW; Lee SS
    Eur Radiol; 2021 Jul; 31(7):4751-4763. PubMed ID: 33389037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Korean Liver Cancer Association-National Cancer Center 2018 Criteria for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using Magnetic Resonance Imaging.
    Lee S; Kim MJ
    J Liver Cancer; 2020 Sep; 20(2):120-127. PubMed ID: 37384315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
    Kang HJ; Lee JM; Yoon JH; Han JK
    Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Four Diagnostic Guidelines for Hepatocellular Carcinoma Using Gadoxetic Acid-enhanced Liver MRI.
    Yoon JH; Kim YK; Kim JW; Chang W; Choi JI; Park BJ; Choi JY; Kim SS; Park HS; Lee ES; Yu JS; Park SJ; You MW; Lee CH; Lee JM
    Radiology; 2024 Apr; 311(1):e233114. PubMed ID: 38563667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC.
    Min JH; Kim JM; Kim YK; Kim H; Cha DI; Kang TW; Choi GS; Choi SY; Ahn S
    Liver Int; 2021 Dec; 41(12):2986-2996. PubMed ID: 34242468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.